X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES NOVARTIS VENUS REMEDIES/
NOVARTIS
 
P/E (TTM) x -9.9 284.5 - View Chart
P/BV x 0.2 24.2 0.6% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 VENUS REMEDIES   NOVARTIS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
NOVARTIS
Mar-17
VENUS REMEDIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs143855 16.7%   
Low Rs65666 9.8%   
Sales per share (Unadj.) Rs324.2219.0 148.0%  
Earnings per share (Unadj.) Rs6.419.1 33.6%  
Cash flow per share (Unadj.) Rs40.620.3 199.9%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs366.0307.0 119.2%  
Shares outstanding (eoy) m12.3429.96 41.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.5 9.2%   
Avg P/E ratio x16.239.8 40.7%  
P/CF ratio (eoy) x2.637.5 6.8%  
Price / Book Value ratio x0.32.5 11.5%  
Dividend payout %052.4 0.0%   
Avg Mkt Cap Rs m1,28222,779 5.6%   
No. of employees `0000.90.7 134.0%   
Total wages/salary Rs m2511,393 18.0%   
Avg. sales/employee Rs Th4,430.19,736.2 45.5%   
Avg. wages/employee Rs Th278.02,066.8 13.4%   
Avg. net profit/employee Rs Th87.6849.0 10.3%   
INCOME DATA
Net Sales Rs m4,0006,562 61.0%  
Other income Rs m23702 3.2%   
Total revenues Rs m4,0237,264 55.4%   
Gross profit Rs m785259 303.1%  
Depreciation Rs m42236 1,174.4%   
Interest Rs m3447 4,773.6%   
Profit before tax Rs m42917 4.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37345 -10.7%   
Profit after tax Rs m79572 13.8%  
Gross profit margin %19.63.9 497.2%  
Effective tax rate %-87.937.6 -233.6%   
Net profit margin %2.08.7 22.7%  
BALANCE SHEET DATA
Current assets Rs m2,6069,731 26.8%   
Current liabilities Rs m1,9801,830 108.2%   
Net working cap to sales %15.6120.4 13.0%  
Current ratio x1.35.3 24.8%  
Inventory Days Days12849 263.5%  
Debtors Days Days4325 171.5%  
Net fixed assets Rs m5,35357 9,358.8%   
Share capital Rs m123141 87.7%   
"Free" reserves Rs m4,3939,056 48.5%   
Net worth Rs m4,5169,196 49.1%   
Long term debt Rs m1,6180-   
Total assets Rs m8,29111,499 72.1%  
Interest coverage x1.1128.4 0.9%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.6 84.6%   
Return on assets %5.15.0 101.2%  
Return on equity %1.86.2 28.2%  
Return on capital %6.310.1 62.6%  
Exports to sales %00-   
Imports to sales %18.40-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m736NA-   
Fx inflow Rs m0129 0.0%   
Fx outflow Rs m7361,734 42.5%   
Net fx Rs m-736-1,605 45.9%   
CASH FLOW
From Operations Rs m997-380 -262.8%  
From Investments Rs m-4614,208 -11.0%  
From Financial Activity Rs m-571-3,318 17.2%  
Net Cashflow Rs m-35510 -6.9%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 2.0 9.0%  
FIIs % 0.6 1.6 36.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 21.5 308.8%  
Shareholders   20,121 41,647 48.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   STRIDES SHASUN LTD  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 15, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - PANACEA BIOTECH COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS